Jesse M. Cedarbaum

TL;DR: Current standards for detecting and defining the clinical presentation of AD were reviewed and areas that could contribute to earlier and more accurate definitive clinical diagnosis were discussed, including clinical, neuropsychological, and other performance‐based assessments, genetic contributions, and biochemical and neuroimaging biomarkers that could reflect AD pathology and lead to better ascertainment of AD.

TL;DR: A comprehensive outcome measure such as the Clinical Dementia Rating Sum of Boxes (CDR-SB), which has components that assess both cognitive and functional domains in parallel deserves consideration as a primary outcome measure for early AD clinical trials.

TL;DR: Increased NMSC incidence (especially SCC) and inversion of BCC:SCC ratio suggest that Notch inhibition oncogenically effects SCC, and may help accurately identify and manage skin malignancies in studies using agents that affect epidermal differentiation.

TL;DR: Neuropsychiatric symptoms (NPS) are core features of Alzheimer's disease and related dementias as mentioned in this paper, and despite decades of research, reliable treatments for dementia-associated NPS have not been found, and these symptoms are currently knowntomanifestcommonlyinveryearlydiseaseandinprodromalphases, such as mild cognitive impairment.